News

SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023.

“Hundreds of organizations have been selected to join each network. Having been asked to become a member on both networks is a rare opportunity — SRI is honored,” said Kathlynn Brown, president of SRI’s Biosciences division.

Through these memberships, SRI gains access to potential funding and flexible contracting for faster award execution compared to traditional contract processes. This means that people can benefit from advanced healthcare innovations in discovery and treatment without having to wait for years.

The Customer Experience Hub seeks to make healthcare treatments accessible to everyone, from rural areas to cities. The Investor Catalyst Hub seeks to accelerate the broad commercialization of groundbreaking biomedical solutions. The networks utilize an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and minority-serving institutions, to deliver scalable positive healthcare outcomes for all Americans.

SRI delivers bioscience, applied research, and commercial transfer expertise — moving important health technologies from the research lab into the real world.

“SRI’s mission is to make an impact so people can live healthier and safer lives,” said Brown. “We’re proud to be a part of this nationwide health initiative to advance our innovations where they can make a difference. Our work in precision medicine is essential, but without government and commercial support, people, especially in rural and underserved areas, cannot benefit.”

SRI joins a nationwide network of organizations aligned to ARPA-H’s overarching mission of improving health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. ARPANET-H hubs and spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.

“The ARPA-H model is advantageous because the trusted members can move quickly, so the proper healthcare can be delivered faster and safer,” Brown said.

 

Learn more here.

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …